Tumor Board Review, Second Edition: Guideline and Case Reviews in Oncology

Praise for the First Edition“As everyone in oncology fellowship training knows, there is a huge [information] gap in this field. Most oncology books are massive and loaded with information…by the time the book is [published]…it is outdated.” [Tumor Board Review] is fresh and just out of the oven…I haven’t seen any book in oncology like this so far…I think my investment in this book was wise and worth it.” — Humaid Al-Shamsi, MB(Hon), BMedSc, MRCP(UK), FRCP, FACP, Assistant Professor, The University of Texas, MD Anderson Cancer CenterCulling the knowledge and expertise of respected oncology specialists, this is a concise yet comprehensive review of all areas of oncology practice for medical oncologists, radiation oncologists, and pathologists — both students and practitioners. The second edition of Tumor Board Review has been thoroughly revised to encompass recent scientific advances in assessment and treatment, new clinical guidelines, and new FDA-approved drugs and indications. It also contains approximately 250 multiple-choice questions and answers to assist readers in testing their knowledge, especially those preparing for the MOC exam.The book features case presentations and evidence-based management discussions that clearly demonstrate how to apply new information in daily practice. In a consistent format, each chapter addresses epidemiology, risk factors, natural history, and pathology of each major organ-specific tumor type; an abbreviated display of relevant staging; and several “tumor board style” illustrative patient case studies. This is followed by an evidence-based case discussion, which reinforces current guidelines and explains the rationale for the diagnostic and therapeutic steps taken. Algorithms and decision-tree graphics further illuminate the decision process.NEW TO THE SECOND EDITION OF TUMOR BOARD REVIEW: Presents the most recent guidelines and management standards in user-friendly format Focuses on current indications, use of new drugs, and new treatment of side effects Includes new FDA-approved drugs and guidelines Offers approximately 250 multiple-choice questions and answers

About the Author

Kathleen A. Cooney, MD, is Professor and Chair, Department of Internal Medicine at the University of Utah Teresa G. Hayes, MD, PhD, Assistant Professor of Oncology, Baylor College of Medicine Martha Pritchett Mims, MD PhD is Professor and Chief of Hematology-Oncology at Baylor College of Medicine in Houston, Texas. Robert F. Todd III, MD, PhD, Chair of Medicine, Baylor College of Medicine Francis P. Worden, MD is a Professor of Medicine and Director of the Hematology/Oncology Fellowship Program at the University of Michigan Medical School in Ann Arbor, Michigan.